Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys.
BACKGROUND
When given during pregnancy, the drug 3'-azido-2',3'-dideoxythymidine (AZT) substantially reduces maternal-fetal transmission of human immunodeficiency virus type 1 (HIV-1). However, AZT has been shown to be carcinogenic in adult mice after lifetime oral administration. In this study, we assessed the transplacental tumorigenic and genotoxic effects of AZT in the offspring of CD-1 mice and Erythrocebus patas monkeys given AZT orally during pregnancy.


METHODS
Pregnant mice were given daily doses of either 12.5 or 25.0 mg AZT on days 12 through 18 of gestation (last 37% of gestation period). Pregnant monkeys were given a daily dose of 10.0 mg AZT 5 days a week for the last 9.5-10 weeks of gestation (final 41%-43% of gestation period). AZT incorporation into nuclear and mitochondrial DNA and the length of chromosomal end (telomere) DNA were examined in multiple tissues of newborn mice and fetal monkeys. Additional mice were followed from birth and received no further treatment until subjected to necropsy and complete pathologic examination at 1 year of age. An anti-AZT radioimmunoassay was used to monitor AZT incorporation into DNA.


RESULTS
At 1 year of age, the offspring of AZT-treated mice exhibited statistically significant, dose-dependent increases in tumor incidence and tumor multiplicity in the lungs, liver, and female reproductive organs. AZT incorporation into nuclear and mitochondrial DNA was detected in multiple organs of transplacentally exposed mice and monkeys. Shorter chromosomal telomeres were detected in liver and brain tissues from most AZT-exposed newborn mice but not in tissues from fetal monkeys.


CONCLUSIONS
AZT is genotoxic in fetal mice and monkeys and is a moderately strong transplacental carcinogen in mice examined at 1 year of age. Careful long-term follow-up of AZT-exposed children would seem to be appropriate.
Olivero
O A
OA
Division of Basic Sciences, National Cancer Institute, Bethesda, MD 20892-4255, USA. olivero@pop.nci.nih.gov
Anderson
L M
LM
Diwan
B A
BA
Haines
D C
DC
Harbaugh
S W
SW
Moskal
T J
TJ
Jones
A B
AB
Rice
J M
JM
Riggs
C W
CW
Logsdon
D
D
Yuspa
S H
SH
Poirier
M C
MC
D000818:Animals; D000831:Animals, Newborn; D002273:Carcinogens / Q000009:adverse effects*; D004272:DNA, Mitochondrial / Q000187:drug effects; D004273:DNA, Neoplasm / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004901:Erythrocebus patas; D005260:Female; D005333:Fetus / Q000187:drug effects; D051379:Mice; D008815:Mice, Inbred Strains; D010920:Placenta; D011247:Pregnancy; D011863:Radioimmunoassay; D016615:Telomere / Q000187:drug effects; D015215:Zidovudine / Q000009:adverse effects*
D002273:Carcinogens; D004272:DNA, Mitochondrial; D004273:DNA, Neoplasm; D015215:Zidovudine